Teva will it follow the BMS way?

After the investor's day update last week that Teva will be saving around USD 2 Billion of cash going forward. Mr Jermy levin has started implementing the process. Today Teva announced that its scrapping a $300 million warehouse project in Philadelphia has been halted.

Levin recently laid out a 5-year plan to diversify the company's products and to save up to $2 billion in large part by making its manufacturing operations more efficient. 

In light of the evaluation, a spokesperson said in an emailed statement, "As such, we have made the decision to cease development plans for the proposed distribution center on Red Lion Road in Philadelphia. At this time we cannot elaborate further about plans for this property."

What will be interesting going forward that there will be more possibility that Teva will also collaborate with some big Asian generic/biopharma companies for small molecule development the same lines BMS did with research outsourcing to India based Biocon some years back..... As he was key stakeholder involved in the famous BMS- Biocon alliance in India. Will Jermy move that way only time will say? 

CRO's New Marketing game!

Today at one side I have been down with fever but one promotion by Quintiles intrigued me " Quintiles: your RA partner"


RA landscape has been the most interesting landscape both in terms of small molecules and bio generics....Abbott had already been a market leader in terms of Humira but Pfizer has big plans for capturing the market share and we need to look at how it’s going to go for its pricing so that it has quick approval from the regulatory bodies in European region...
Now we need to just see if quintiles is going to be trials partner for the major companies who are investing in this segment for both the big daddy’s and bio generics and generic manufacturers in the RA landscape as compared to oncology its comparative easy market entry......What will be the next strategy for Icon, Paraxel, PPD and convance?

Teva the giant......Will it be major contributor in Pharma Consolidation?

Jermy Levin became a Teva CEO long time back and I think has completed his probation period. Teva as a company is very conservation on its approach in advancement in any particular space in terms of indication attractiveness and product opportunities. After long time I was hearing Jermy Levin speak about its move....Teva for some time has been dwindling in a particular frame of mind as being a generic player or move differently the innovative path. What I am very positive about is that Jermy Levin was one of kind who made difference for BMS and i hope that he will have better success story to be told in future for Teva.........Teva like Novartis will be a one of the key player of the next Pharma consolidation happening by year 2020